BCKDHB

BCKDHB encodes the E1β subunit of the mitochondrial branched-chain α-ketoacid dehydrogenase (BCKDH) complex, the enzyme system responsible for catabolism of the branched-chain amino acids leucine, isoleucine, and valine (PMID:40009698). Functional reconstitution shows that E1β (BCKDHB) must be co-expressed with E1α (BCKDHA) to form the active E1 component required for holoenzyme activity; co-delivery of both subunits restores BCKDH activity in deficient cells and in vivo, whereas neither subunit alone is sufficient (PMID:40009698). Restoration of BCKDHB expression alone rescues complex activity in a Bckdhb-null background, establishing that loss of this subunit is the limiting defect in those animals (PMID:36880392). Loss of BCKDHB activity causes maple syrup urine disease, and AAV-mediated gene delivery normalizes branched-chain amino acid biomarkers and rescues the lethal phenotype in vivo (PMID:36880392, PMID:40009698). Beyond the requirement for β–β' and β–α subunit contacts in assembling the active E1 component (PMID:22326532), no further mechanistic detail of the catalytic cycle has been characterized in the available corpus.

1. 1991 Medium

   Establishing the genomic position of BCKDHB was the first step toward linking the E1β subunit gene to its locus and to disease mapping.

   Evidence Somatic cell hybrid analysis and in situ hybridization localizing the gene to chromosome 6p21-22

   PMID:1889817

   Open questions at the time

   • Does not address protein function or assembly
   • No connection to enzyme activity demonstrated at this stage
2. 2012 Low

   Mapping disease-associated missense mutations onto E1 structure addressed which residues are required for subunit assembly, implicating β–β' and β–α interface contacts in E1 integrity.

   Evidence Molecular modeling of R170H and Q346R mutations combined with clinical Sanger sequencing

   PMID:22326532

   Open questions at the time

   • Structural effects inferred solely from in silico modeling without in vitro biochemical validation
   • No measurement of residual enzyme activity for the mutant proteins
   • Assembly defects not confirmed by structural or biophysical methods
3. 2023 Medium

   Whether restoring BCKDHB alone could re-establish functional complex activity was answered by gene-replacement rescue in a knockout model, confirming BCKDHB as the limiting defect in Bckdhb-null animals.

   Evidence Neonatal AAV8 delivery of human BCKDHB cDNA in Bckdhb-/- mice with MSUD biomarker normalization

   PMID:36880392

   Open questions at the time

   • Single lab, single study
   • Does not resolve the stoichiometry or co-assembly requirements with other subunits
   • Tissue-specific contributions to whole-body rescue not dissected
4. 2025 High

   Whether E1α and E1β must be jointly expressed to reconstitute the active E1 component was answered by dual-subunit co-delivery, confirming both BCKDHA and BCKDHB are required to rebuild holoenzyme activity.

   Evidence Dual-gene rAAV9 vector reconstitution in HEK293T cells with enzyme activity assays plus in vivo rescue in two knockout mouse models and a BCKDHA-mutant calf

   PMID:40009698

   Open questions at the time

   • Atomic-resolution structure of the human E1 heterotetramer not determined here
   • Catalytic mechanism and cofactor handling within the complex not detailed
   • Regulation of BCKDH activity not addressed

• The catalytic and regulatory mechanism of the BCKDHB-containing E1 component, including its cofactor chemistry and integration with E2/E3 in the holoenzyme, remains uncharacterized in this corpus.
• No experimental structure of the human E1 heterotetramer in the timeline
• No direct biochemical dissection of decarboxylation chemistry by BCKDHB-containing E1
• Regulatory control of complex activity not addressed